- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
Patent holdings for IPC class A61P 9/04
Total number of patents in this class: 2203
10-year publication summary
|
60
|
95
|
130
|
124
|
130
|
152
|
156
|
158
|
155
|
46
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Cytokinetics, Inc. | 256 |
49 |
| Daiichi Sankyo Company, Limited | 1887 |
44 |
| Novartis AG | 10346 |
34 |
| Amgen Inc. | 4348 |
32 |
| Takeda Pharmaceutical Company Limited | 2718 |
32 |
| Osaka University | 3304 |
28 |
| Bristol-myers Squibb Company | 4812 |
26 |
| AstraZeneca AB | 2836 |
22 |
| Mitsubishi Tanabe Pharma Corporation | 437 |
21 |
| Boehringer Ingelheim International GmbH | 4529 |
18 |
| MyoKardia, Inc. | 110 |
18 |
| Cardioxyl Pharmaceuticals, Inc. | 46 |
17 |
| Boehringer Ingelheim Vetmedica GmbH | 1269 |
16 |
| Bayer Pharma AG | 1029 |
16 |
| Sunshine Lake Pharma Co., Ltd. | 618 |
15 |
| Imbria Pharmaceuticals, Inc. | 67 |
15 |
| The Regents of the University of California | 20534 |
14 |
| Bayer AG | 3435 |
14 |
| Shionogi & Co., Ltd. | 862 |
14 |
| Japan Tobacco Inc. | 3504 |
13 |
| Other owners | 1745 |